Shingles Vaccine Market

Shingles Vaccine Market Outlook (2024 to 2034)

Revenue from the global shingles vaccine market size is estimated at US$ 2.71 billion in 2024. The market is analyzed to climb to a value of US$ 5.97 billion by the end of 2034, expanding at a CAGR of 8.2% from 2024 to 2034.

Shingles is a viral infection that leads to a painful rash. Shingles can appear anywhere on the body. It usually appears as a single band of blisters around the torso, either on the left or right side.

The varicella-zoster virus, which also causes chickenpox, is the source of shingles. The virus that causes chickenpox remains in your body for the duration of your life. The virus may reactivate as shingles years later. There is no risk to life from shingles but the pain can be excruciating. Vaccines can reduce the chance of developing shingles. Treatment for shingles early on can reduce the duration of the infection and lower the risk of complications.

Key Market Growth Drivers

• Increased risk of developing shingles, especially in those 60 years of age and older, as well as improvements in healthcare facilities in developed countries, are the main drivers of shingles vaccine market growth.
• Shingrix prevents shingles from occurring again if one has already had the illness. There is no set amount of time one needs to wait to receive the Shingrix vaccine after developing shingles, but generally, it is advised to wait until the rash has healed before receiving the shot.
• Trend toward innovative recombinant vaccines is expected to fuel market expansion.
  • Since 2006, adults over 60 years of age were advised to receive a shingles vaccination by the United States Advisory Committee on Immunization Practices.
  • Due to the vaccine's high efficacy, the Centers for Disease Control and Prevention (CDC) recommended Shingrix over Zostavax in January 2018 to prevent Shingles.
• The National Center for Biotechnology Information estimates that in the next 10 years, there will be 278 million cases of herpes zoster worldwide if there is no shingles vaccine. While there are several antiviral treatments for shingles, including acyclovir and valacyclovir, immunization against the herpes zoster virus becomes crucial in patients with compromised immune systems.
• Postherpetic neuralgia (PHN) is not responsive to antiviral treatment. Therefore, during the projected period, the development of an effective vaccine is projected to serve as a driving force for the expansion of the shingles vaccine market size.

Report Attribute	Detail
Shingles Vaccine Market Size (2024E)	US$ 2.71 Billion
Forecasted Market Value (2034F)	US$ 5.97 Billion
Global Market Growth Rate (2024 to 2034)	8.2% CAGR
North America Market Share (2024E)	67.5%
East Asia Market Share (2024E)	9.1%
Revenue from Sales of Recombinant Vaccines (2024E)	US$ 2.29 Billion
Key Companies Profiled	Cipla Inc.; Pfizer Inc.; Merck & Co., Inc.; SK Chemicals; Vaccitech; CanSinoBIO; Green Cross Corp.; GlaxoSmithKline Plc.; GeneOne Life Science.

Why is There Heightened Need for Herpes Zoster Vaccines for the Elderly?

“Increased Risks of Stroke, Pneumonia, and Encephalitis from Shingles among Older Adults”

Due to weakened immune systems brought on by aging, older adults are more vulnerable to developing shingles. Adults over 60 years of age account for half of all shingles cases globally.

• The risk of developing shingles increases over the age of 60, affecting one in three people at some point in their lives, according to the Centers for Disease Control and Prevention (CDC). The immune systems of about 30% of patients admitted to hospitals with shingles are found to be compromised.

Shingles cause additional health problems in older adults, including a higher risk of stroke and other complications such as pneumonia and encephalitis. Consequently, to treat the elderly population, a herpes zoster vaccine that is both safe and affordable is needed.

What are the Factors Affecting the Uptake of Shingles Vaccines?

“Lack of Access to Education Programs Tailored for Particular Demographics”

Significance of the shingles vaccine is not widely understood by the general public. Knowledge about shingles and the importance of immunization varies significantly across the globe. In certain low- and middle-income countries, there may be insufficient public education campaigns regarding shingles and preventive measures.

Limited awareness of vaccines and their advantages leads to low vaccine literacy. Communities with low health literacy often lack awareness about the risks of shingles or the potential benefits of vaccination. Certain communities do not have access to education programs designed with particular demographics in mind, such as older adults who are at risk, in mind. Programs for targeted education do not exist in isolated areas or towns with few medical facilities.

Country-wise Insights

North America is a key market for shingles vaccine providers due to increasing investments in healthcare and a growing geriatric population. Europe is adopting similar measures and building up its healthcare system in tandem. Asia Pacific has room to grow as a result of a growing aging population. Need for vaccines is largely driven by the rising incidence of shingles and initiatives to avoid post-herpetic neuralgia. The introduction of health campaigns and focus on easier access to vaccinations are key shingles vaccine market trends.

Will Aging Population Contribute to Increasing Vaccination Rates in the United States?

“Rising Immunization Recommendations for Older Adults”

Attribute	United States
Market Value (2024E)	US$ 1.78 Billion
Growth Rate (2024 to 2034)	5.8% CAGR
Projected Value (2034F)	US$ 3.14 Billion

Aging is associated with decreased immune function, making people more susceptible to infections. The varicella-zoster virus, which causes shingles, reactivates due in part to the weakened immune systems of the elderly.

• According to estimates from the CDC, one in three Americans will get shingles at some point in their lives which is expected to drive the market in the country.

More than 99% of people in the United States who are 40 years of age and older have symptoms consistent with a history of varicella infection, putting them at risk of developing shingles. As people are aging, vaccination rates also tend to increase, particularly for immunizations recommended for older adults. Healthcare reports indicate that the uptake of the shingles vaccine is rising as vaccination recommendations and awareness campaigns target older populations.

How is Rapid Expansion of Healthcare Infrastructure Influencing Market Growth in China?

“Investments in Healthcare Infrastructure Enhancing Vaccine Accessibility”

Attribute	China
Market Value (2024E)	US$ 132 Million
Growth Rate (2024 to 2034)	11.4% CAGR
Projected Value (2034F)	US$ 390 Million

Increasing burden of infectious diseases, including shingles, is prompting healthcare providers to focus on implementing preventive measures such as vaccination. The expansion of healthcare infrastructure, including vaccination clinics and distribution networks, is helping improve access to vaccines across different parts of China. This infrastructure development contributes to the growing availability and uptake of the shingles vaccine. Government-led vaccination campaigns and subsidies for shingles vaccines are influencing the adoption of the shingles vaccine.

• GlaxoSmithKline (GSK) recently entered into an exclusive partnership with Chongqing Zhifei Biological Products to distribute the Shingrix vaccine in China. Zhifei has agreed to pay £2.5 billion (US$ 3.05 billion) for the exclusive distribution rights from 2024 to 2026 along with a certain volume of the vaccine. This partnership is expected to expedite the availability of Shingrix, since Zhifei can provide about 30,000 vaccination locations throughout China.

Category-wise Insights

The market is categorized into Shingrix, Zostavax, and Sky Zoster, of which Shingrix is set to hold a key shingles vaccine market share of 84.7% in 2024. In terms of end users, private and government healthcare settings are responsible for distributing vaccines to more people.

What is Driving Increasing Demand for Shingrix Vaccines Globally?

“Efficacy of Shingrix in Preventing Herpes Zoster and Post-Herpetic Neuralgia”

Attribute	Shingrix
Segment Value (2024E)	US$ 2.29 Billion
Growth Rate (2024 to 2034)	8.3% CAGR
Projected Value (2034F)	US$ 5.1 Billion

Shingrix is an adjuvant subunit vaccine that includes recombinant VZV glycoprotein E (gE). Those above 50 years use it to prevent herpes zoster (shingles) and post-herpetic neuralgia, which is chronic nerve pain that occurs after shingles.

Since these vaccinations are very effective and have fewer side effects, Shingrix is expected to hold a significant share of the market. Growing demand for these vaccines is driven by rising awareness of the disease's consequences and the growing number of countries that have approved Shingrix for use as a vaccine.

Why Do Government Healthcare Settings Account for a High Number of Shingles Vaccinations?

“Collaborations Between Governments and Vaccine Providers”

Attribute	Government Healthcare Settings
Segment Value (2024E)	US$ 1.6 Billion
Growth Rate (2024 to 2034)	8.5% CAGR
Projected Value (2034F)	US$ 3.62 Billion

Government policies encouraging adult vaccination programs, particularly for the elderly, are helping boost the adoption of shingles vaccines. For example, the Australian Government is collaborating closely with state and territory governments to ensure that Shingrix doses are distributed fairly and appropriately to meet demand.

To guarantee that the local supply is managed fairly and effectively, individual states and territories oversee the distribution of vaccines to local providers. Governments across the world are closely collaborating with vaccine suppliers to investigate potential ways to expedite vaccination in their respective countries.

Competitive Landscape

Key players in the shingles vaccine market are largely aiming at setting up manufacturing facilities, creating more order, and investing in research to develop more effective vaccines.

• Pfizer and BioNTech started their third partnership in January 2022, with Pfizer contributing US$ 225 million. The goal of this collaborative endeavor is to apply RNA technology to the creation of a shingles vaccine. The creation of an effective and tolerable mRNA-based shingles vaccine is the main objective of this collaboration. The development costs of the vaccine will be split between the two companies, and clinical trials are expected to start in the second quarter of 2022.
• GlaxoSmithKline in June 2021 announced that it would relaunch its shingles vaccine after seeing a drop in sales due to disruptions in COVID-19 vaccine rollouts. The company also sought to establish itself as the world's top vaccine producer.

Fact.MR provides detailed information about the price points of key providers of shingles vaccines positioned across the world, sales growth, production capacity, and speculative technological expansion, in this new market report.

Segmentation of Shingles Vaccine Market Research

• By Type :

  • Shingrix
  • Zostavax
  • Sky Zoster

• Vaccine Type :

  • Recombinant Vaccines
  • Live Attenuated Vaccines

• By End User :

  • Government Healthcare Settings
  • Private Healthcare Settings

• By Region :

  • North America
  • Western Europe
  • Eastern Europe
  • Latin America
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa